Senate Bill Would Encourage Adverse-Event Reporting Experimentation
This article was originally published in Clinica
Two senators, one from each party, have introduced a bill that parallels device industry-friendly sections of the 21st Century Cures Act that cleared the House last year, but also adds something new: a provision to give FDA more flexibility to pilot alternatives to the current adverse-event report process.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.